Price$0.22+0.02 (+9.18%)
2026-03-102026-06-11
News · 26 weeks46-20%
2025-12-142026-06-07
Mix2290d
- SEC Filings12(55%)
- Other6(27%)
- Insider4(18%)
Latest news
25 items- SECSEC Form DEFA14A filed by Azitra IncDEFA14A - Azitra, Inc. (0001701478) (Filer)
- SECAzitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Azitra, Inc. (0001701478) (Filer)
- PRAzitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened MeetingBRANFORD, Conn., June 4, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced its 2026 Annual Meeting, originally scheduled for and convened on June 4, 2026, has been adjourned until June 15, 2026, at 11:00 a.m. Eastern Time, because the Company did not have a sufficient number of shares of the Company's common stock present virtually or represented by proxy at the 2026 Annual Meeting to constitute a quorum and to provide stockholders additional time to review the proxy materials and vote at the 2026 Annual Meeting on the proposals outlined below and described in the Com
- SECSEC Form EFFECT filed by Azitra IncEFFECT - Azitra, Inc. (0001701478) (Filer)
- SECSEC Form DEFA14A filed by Azitra IncDEFA14A - Azitra, Inc. (0001701478) (Filer)
- SECAzitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Azitra, Inc. (0001701478) (Filer)
- PRAzitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual MeetingBRANFORD, Conn., May 27, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to convene its upcoming 2026 annual meeting of stockholders (the "2026 Annual Meeting") scheduled for June 4, 2026 at 11:00 a.m., Eastern Time, and then immediately adjourn proceedings, without conducting any other business. Azitra intends to reconvene the 2026 Annual Meeting on June 15, 2026 at 11:00 a.m., Eastern Time (the "Reconvened 2026 Annual Meeting"). The Company has determined to adjourn the 2026 Annual Meeting to allow additional time for stockholders to receive and su
- SECSEC Form S-1 filed by Azitra IncS-1 - Azitra, Inc. (0001701478) (Filer)
- PRAzitra, Inc. Announces Q1 2026 Results and Provides Business UpdatesBRANFORD, Conn., May 13, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2026, and provided a business update. Q1 2026 and Recent Business HighlightsAnnounced the addition of MD Anderson Cancer Center as a clinical site for Phase 1/2 trial of ATR-04 targeting EGFRi-associated skin rash.Launched innovative protein and peptide programs for the cosmetic and cosmeceutical markets l
- SECSEC Form 10-Q filed by Azitra Inc10-Q - Azitra, Inc. (0001701478) (Filer)
- SECAzitra Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Azitra, Inc. (0001701478) (Filer)
- SECSEC Form DEF 14A filed by Azitra IncDEF 14A - Azitra, Inc. (0001701478) (Filer)
- PRAzitra, Inc. Announces New U.S. Patent Protecting ATR-12 ProgramPatent offers broad protections for ATR-12, an engineered strain of S. epidermidis that expresses a fragment of human LEKTI proteinATR-12 is currently the subject of a Phase 1b trial for the treatment of Netherton syndromeBRANFORD, Conn., May 6, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the issuance of a new U.S. patent protecting ATR-12, the company's lead product candidate. Azitra is advancing ATR-12 in a Phase 1b clinical trial as a treatment for Netherton syndrome, a chronic and potentially fatal skin disease that is estimated to affect approximately 20,00
- PRAzitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis VulgarisPreclinical data demonstrate ATR-01 delivers functional filaggrin, restoring skin barrier integrity and supporting advancement toward first-in-human studiesBRANFORD, Conn., April 28, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the presentation of new preclinical data from its ATR-01 program at the 2026 Annual Meeting of the American Society of Gene & Cell Therapy ("ASGCT 2026"). The poster highlights Azitra's engineered live biotherapeutic candidate
- SECSEC Form PRE 14A filed by Azitra IncPRE 14A - Azitra, Inc. (0001701478) (Filer)
- INSIDERSEC Form 4 filed by Whitfill Travis4 - Azitra, Inc. (0001701478) (Issuer)
- INSIDERSEC Form 4 filed by Salva Francisco D.4 - Azitra, Inc. (0001701478) (Issuer)
- INSIDERSEC Form 4 filed by Staskey Norm4 - Azitra, Inc. (0001701478) (Issuer)
- SECAzitra Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Azitra, Inc. (0001701478) (Filer)
- INSIDERSEC Form 4 filed by Salva Francisco D.4 - Azitra, Inc. (0001701478) (Issuer)
- SECAzitra Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - Azitra, Inc. (0001701478) (Filer)
- PRAzitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public AnnouncementBRANFORD, Conn., March 13, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Azitra was not in compliance with the Exchange's continued listing standards under Section 1003(a)(iii) of the NYSE American Company Guide (the "Company Guide"). Section 1003(a)(iii) requires a listed company to have stockholders' equity of $6 million or more if the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. As previously reported, on Octobe
- SECSEC Form DEFA14A filed by Azitra IncDEFA14A - Azitra, Inc. (0001701478) (Filer)
- SECAzitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Azitra, Inc. (0001701478) (Filer)
- PRAzitra, Inc. Announces Cancellation of 2026 Special Meeting of StockholdersBRANFORD, Conn., March 5, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR) ("Azitra" or the "Company"), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has cancelled the Company's special meeting of stockholders that was originally scheduled for February 6, 2026, but was adjourned due to a lack of quorum until March 6, 2026. About AzitraAzitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. Azitra's lead program, ATR-12,
AZTR FAQ
5 questionsWhere does AZTR stock trade?
Azitra Inc (AZTR) is listed on AMEX.What sector and industry is AZTR in?
Azitra Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Azitra Inc go public?
Azitra Inc (AZTR) completed its IPO in 2023.What companies are similar to AZTR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AZTR side-by-side with any of them on Quantisnow.How can I track AZTR on Quantisnow?
Quantisnow aggregates Azitra Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AZTR to receive live email and push alerts on every new disclosure.